Leadership
e-Newsletter
Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Senate panel hits Sanofi payments

The Wall Street Journal, May 25, 2011

Sanofi SA contributed more than $5 million to two medical groups and a medical researcher that encouraged U.S. regulators to delay approval of a drug that would undercut the company's blockbuster blood-thinner Lovenox, according to a new report from the Senate Finance Committee. Letters to the FDA from the groups--the Society of Hospital Medicine and the North American Thrombosis Forum—and the researcher, Victor Tapson, a thrombosis expert at Duke University, said that generic versions of Lovenox, a fast-acting anticlotting medicine, might not be as safe as the brand-name drug, according to the report. The letters didn't mention financial ties to Sanofi.